Lantern Pharma Inc.
NASDAQ:LTRN
3.31 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Lantern Pharma Inc. |
Symbool | LTRN |
Munteenheid | USD |
Prijs | 3.31 |
Beurswaarde | 35,631,157 |
Dividendpercentage | 0% |
52-weken bereik | 2.72 - 11.99 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Panna Sharma PH.D. |
Website | https://www.lanternpharma.com |
An error occurred while fetching data.
Over Lantern Pharma Inc.
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)